Dapagliflozin (Farxiga)
SGLT2 inhibitor · SGLT2 class · oral smd · AstraZeneca
Top dose
10 mg
HbA1c reduction
-0.70%
at week 24 · efficacy
AE discontinuation
5.0%
Status
approved
Pivotal trial
- Trial
- DECLARE-TIMI 58 (HbA1c)
- Indication
- type 2 diabetes
- Duration
- 24 weeks
- ClinicalTrials.gov
- NCT01730534
- Sponsor
- AstraZeneca
Notes
HbA1c effect ~-0.7%; the franchise value is cardio-renal (DAPA-HF, DAPA-CKD outcome wins). AstraZeneca's anchor cardiometabolic SGLT2.